ASLAN Pharmaceuticals (NASDAQ:ASLN) reported positive topline data from its Phase 2b dose-ranging study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis, which is often referred to as eczema.
Eblasakimab met the primary endpoint of percent change from baseline in the Eczema Area and Severity Index score at week 16 versus placebo with statistical significance in three dosing arms: 600 mg dosed once every four weeks which was numerically the best performing arm; 400 mg dosed once every two weeks; and 300 mg dosed once every two weeks.
Eblasakimab is a novel monoclonal antibody targeting the IL-13 receptor subunit of the Type 2 receptor, a key pathway driving several allergic inflammatory diseases.
“This is the first time we’ve seen a once-a-month treatment option deliver competitive efficacy data, which would be a game-changer for patients with AD,” said Eric Simpson, M.D., Frances J. Storrs Professor of medical dermatology at the Oregon Health and Science University and lead investigator in the TREK-AD study, said in a statement.
“These results support eblasakimab’s potential to be a leading therapy for the treatment of atopic dermatitis, if approved,” he added.
Carl Firth, CEO of ASLAN, said “We look forward to advancing quickly into a Phase 3 program in atopic dermatitis, and exploring the broad range of indications where we would expect this drug candidate to be successful.”
